Pathologic and Molecular Characterization of Branch Duct Intraductal Papillary Mucinous Neoplasm With Advanced Neoplasia Under-Recognized by Kyoto High-Risk Stigmata
OBJECTIVES: Kyoto high-risk stigmata (HRS) guide resection of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) but miss a substantial proportion of high-grade dysplasia or invasive carcinoma (HGD/IC). We characterized the pathologic, molecular, and anatomic features of HGD/IC that Kyoto HRS fail to identify, and examined whether they are detectable before surgery by endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE) and cyst-fluid molecular analysis. METHODS: BD-IPMNs resected from 2015 to 2024 in two prospective trials were retrospectively analyzed. Dysplasia and IPMN-subtype were reassessed by blinded pancreaticobiliary pathologists with consensus and immunohistochemistry. Papillary architecture was classified as macropapillary versus non-macropapillary (micropapillary or flat). Diagnostic performance for HGD/IC was assessed against the consensus pathology reference standard. RESULTS: Among 68 BD-IPMNs, 26 (38.2%) had HGD/IC, concentrated in non-macropapillary lesions (53.1%, 17/32, vs. 25.0%, 9/36; P=0.017), with the micropapillary pattern carrying the highest proportion (71.4%, 10/14). GNAS mutation was less frequent in non-macropapillary than macropapillary lesions (25.0% vs. 85.2%; P<0.001). Kyoto HRS were highly specific (95.2%) but only 53.8% sensitive; among 52 HRS-negative lesions, 23.1% (12/52) harbored HGD/IC, predominantly non-macropapillary, GNAS-negative, and located in the body or tail. Adding EUS-nCLE raised sensitivity from 52% to 80% (McNemar P=0.016) at 81% specificity, but nCLE was least sensitive in non-macropapillary lesions (43.8%), where absent GNAS provided a complementary preoperative marker. CONCLUSIONS: The HGD/IC missed by Kyoto HRS was characteristically micropapillary, GNAS-negative, and/or in the body or tail. Because architecture and subtype are histopathologic, preoperative recognition rests on combining Kyoto HRS, EUS-nCLE, and cyst-fluid molecular testing. Prospective external validation is warranted.
Authors
- Stacey Culp (ORCID: https://orcid.org/0000-0002-9180-6426)
- Tassiana G. Maloof
- Zobeida Cruz‐Monserrate (ORCID: https://orcid.org/0000-0003-0849-655X)
- Somashekar Gopala Krishna (ORCID: https://orcid.org/0000-0001-5748-7890)
- Phil A. Hart (ORCID: https://orcid.org/0000-0003-4346-6196)
- Ashwini Kumar Esnakula (ORCID: https://orcid.org/0000-0001-6029-0124)
- Zarine K. Shah (ORCID: https://orcid.org/0000-0002-0354-9678)
- Timothy Michael Pawlik (ORCID: https://orcid.org/0000-0002-7994-9870)
- Wendy L. Frankel (ORCID: https://orcid.org/0000-0003-1658-1009)
- Jorge D. Machicado (ORCID: https://orcid.org/0000-0002-2065-1367)
- Wei Chen (ORCID: https://orcid.org/0000-0003-4610-8490)
- Ahmed Abdelbaki (ORCID: https://orcid.org/0000-0001-6280-415X)
Institutions
- University of Michigan (US)
- The Ohio State University Wexner Medical Center (US)
- Michigan Medicine (US)
- The Ohio State University (US)
Publication Details
- Journal
- Pancreas
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1097/mpa.0000000000002736
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00